March 13, 2026 3 min read Add Us On Google Add SciAm AI-designed experiments run by robots hint at a new approach to biology Researchers at OpenAI and Ginkgo Bioworks showed that an AI model working with an autonomous lab can design and iterate real biology experiments at unprecedented speed By Deni Ellis Béchard edited by Eric Sullivan Technicians move through Ginkgo Bioworks’ automated, robot-run lab, where machines handle high-volume biological research and testing. Gingko Bioworks Join Our Community of Science Lovers! Sign Up for Our Free Daily Newsletter Enter your email I agree my information will be processed in accordance with the Scientific American and Springer Nature Limited Privacy Policy . We leverage third party services to both verify and deliver email. By providing your email address, you also consent to having the email address shared with third parties for those purposes. Sign Up OpenAI’s GPT can summarize research papers and make predictions—but can it do science? Can it generate hypotheses, design experiments, interpret results and iterate? Last summer researchers at OpenAI and Ginkgo Bioworks, a company that designs and installs autonomous, robot-run labs, decided to find out. Though artificial intelligence systems have posted high scores in math, physics and computer science, biology is harder to measure, says Joy Jiao, who leads life sciences research at OpenAI. “For something like ‘design the optimal experiment,’ there’s no right answer. It’s what we call a hard-hard problem: it’s hard to generate a solution, and it’s also really hard to verify.” That led the team to have AI design experiments using superfolder green fluorescent protein (sfGFP), an engineered jellyfish protein that is a common benchmark because it provides a fast, unambiguous signal: it glows green. While OpenAI’s GPT-5 provided the experimental designs, Ginkgo Bioworks provided what its co-founder and CEO Jason Kelly calls the “Waymo” of biology: an automated lab system where researchers set objective and the AI does the driving. The autonomous robotic lab can rapidly process experiments and operate without constant human oversight. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing . By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. The team focused its experiment on cell-free protein synthesis (CFPS), a technique for producing proteins without living cells. Traditional biomanufacturing relies on genetically modifying living cells to produce medicines like insulin. CFPS makes proteins outside of cells by running the cell’s own protein-making machinery in a controlled mixture. “It is one of the fastest ways to make proteins,” says Reshma Shetty, chief operating officer and co-founder of Ginkgo Bioworks. “You don’t need to clone your DNA, put it into the cell and wait for the cell to grow up.” Improving CFPS could have significant implications for medicine, food and agricultural products. From OpenAI’s San Francisco, Calif., headquarters, GPT-5 designed experiments and sent them across the country to Ginkgo Bioworks’ robotic systems in Boston. As it iterated, GPT-5 analyzed incoming data and proposed new experiments, which took about an hour per cycle. “In the time it would take for a human to get their coffee, sit down at their computer, log in and get all set up to do work, the model could take in the data, analyze it and propose new experiments,” Shetty says. “At the beginning of this project, I didn’t know if we could design a single experiment,” Jiao says. “I can remember when the experimental results came back, the reaction from both sides was like, oh, we made a non-zero amount of protein—and that was somewhat surprising.” After two months and more than 36,000 tests of unique reaction compositions, the AI-driven system reduced the cost of producing the protein by about 40 percent compared with a previously reported benchmark from bioengineer Michael Jewett’s lab at Stanford University. “Honestly, it’s a pretty big deal,” says Jewett, whose lab published its own benchmark paper last week in Nature Communications . “How do we develop medicines faster to get lifesaving therapeutics to patients sooner? I think the integration of artificial intelligence and autonomous labs is one way to do that.” The OpenAI–Ginkgo Bioworks collaboration also produced one moment of unexpected novelty. When the team gave GPT-5 access to new reagents, “it tried to squeeze in as many as it possibly could,” Jiao says. “So what the model did was set the amount of water to something negative.” Starting an experiment with a